Extract to table

We have identified the following three highest-priority risk areas that require the Board's particular attention and that must be addressed through robust contractual protections in the SPA: 1

The standard carve-outs for "conditions affecting the pharmaceutical or biotechnology industries generally" must not be drafted so broadly as to sweep in Veridian-specific clinical data

2(b) include a specific closing condition requiring that no MAE shall have occurred between the date of the SPA and the closing date

The change-of-control consent requirements in the Aethon Biologics CMO agreement and the GW Cambridge Properties lease are the only consent requirements that must be addressed in connection with the Transaction